Molecular genetics of prostate cancer

Cory Abate-Shen1,2,4,5 and Michael M. Shen1,3–5

1Center for Advanced Biotechnology and Medicine, 2Department of Neuroscience and Cell Biology, 3Department of Pediatrics, 4Dean and Betty Gallo Prostate Cancer Center, Cancer Institute of New Jersey, UMDNJ–Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA

Prostate cancer afflicts one man in nine over the age of 65 and represents the most frequently diagnosed cancer in American men [Coffey 1993]. Early detection through serum testing for prostate specific antigen [PSA] and improved procedures for surgical intervention and radiation therapy have significantly reduced the number of fatalities; however, there is still no effective cure for men with advanced disease. Therefore, much research has been dedicated to identifying prognostic markers that distinguish indolent versus aggressive forms of prostate cancer. In contrast, significantly less research has been devoted to understanding the molecular mechanisms that underlie normal prostate growth and development or cancer initiation and progression.

In this review, we address recent progress toward the central objectives of understanding parameters of normal versus abnormal prostatic development and of elucidating a molecular pathway for prostate cancer progression. We focus on key regulatory molecules that have been implicated by analysis of patterns of allelic loss in human prostate cancers and/or by reverse genetic approaches in the mouse.

Characteristic features of prostate cancer

Most prostate tumors are adenocarcinomas, sharing numerous common features with other prevalent epithelial cancers, such as breast and colon cancer. Here, we introduce certain salient aspects of prostate cancer that are relevant for investigation of the disease process.

Correlation with aging

A distinguishing feature of prostate cancer is its intimate association with aging; indeed, aging is the single most significant risk factor for prostate cancer. Although preneoplastic lesions known as prostatic intraepithelial neoplasia [PIN] can be found in men in their twenties and are fairly common in men by their fifties [Sakr et al. 1993], clinically detectable prostate cancer is not generally manifest until the age of 60 or 70. Furthermore, the occurrence of precancerous lesions is significantly more prevalent (~1 in 3 men) than the incidence of carcinoma (~1 in 9 men). Therefore, whereas the morphological changes associated with initiation are relatively common and occur early in life, progression to invasive carcinoma is a significantly less common event that occurs in a more limited population as a consequence of aging.

Environmental factors

The incidence of prostate cancer in the United States is significantly higher than in most other countries, particularly Asian countries, even though the incidence of histological pre-neoplastic lesions has been reported to be similar worldwide [Dhom 1983]. Dietary and environmental factors have therefore been presumed to play a key role in prostate carcinogenesis [Carter et al. 1990a], similar to their role in other common epithelial cancers. Recent evidence, however, has thrown into question whether there actually are differences in the relative incidence of preneoplastic lesions in Asian versus American men [Miller 2000].

Familial inheritance

Hereditary factors account for a relatively small percentage (~10%) of prostate cancers and are generally associated with early onset disease [Cannon et al. 1982, Carter et al. 1992, 1993]. To date, two familial susceptibility loci have been mapped to the X chromosome and to a region of chromosome 1q [Smith et al. 1996; Xu et al. 1998], although the respective candidate genes have not yet been identified. In addition, several studies have identified a statistical association between breast and prostate cancer [Thiessen 1974; Anderson and Badzioch 1992, Tulinius et al. 1992], but the molecular basis for such a link is unresolved.

Role of steroid hormones

Steroid hormone receptor signaling plays a pivotal role in all stages of prostate carcinogenesis. In particular, there is a characteristic age-related decrease in the ratio of an-
drogens to estrogens in men, which may represent a contributing factor in prostate cancer initiation (Mawhinney and Neubauer 1979; Dai et al. 1981; Prehn 1999). In addition, the transition to androgen independence that is a hallmark of advanced prostate cancer has been a focus of numerous investigations.

**Heterogeneity and multifocality**

The heterogeneous and multifocal nature of prostate cancer lesions poses significant difficulties for researchers. With regard to heterogeneity, histological inspection of prostate cancer tissue typically reveals a juxtaposition of benign glands, preneoplastic [PIN] foci, and neoplastic foci of varying severity (Fig. 1). To account for this heterogeneity, Gleason proposed a grading system that is now the predominant system used by pathologists, since it is an excellent prognostic indicator. In this system, a score is given based on the sum of the two most prevalent grades of neoplastic foci (e.g., 3 + 3; 3 + 4); a higher Gleason grade indicates a more advanced carcinoma (Gleason 1992).

With regard to multifocality, individual neoplastic lesions within a given section of prostate cancer tissue have been described as genetically distinct (nonclonal), even those in close proximity (e.g., Bostwick et al. 1998; Macintosh et al. 1998). This observation suggests that multiple neoplastic foci may emerge and evolve independently, which has significant implications for the molecular mechanisms of disease progression.

From a practical standpoint, the heterogeneity and multifocality of prostatic lesions, combined with the relatively small size of the prostate, make it difficult to obtain reasonably homogeneous material in sufficient quantities for molecular analysis. These factors represent significant limitations in identifying regulatory genes associated with prostate carcinogenesis, as well as in defining a molecular pathway for the initiation and progression of prostate cancer. In recent years, these difficulties have been partially circumvented by microdissection and laser-capture microscopy approaches that facilitate analysis of individual neoplastic foci (Emmert-Buck et al. 1995, 1996; Macintosh et al. 1998), and by cell-sorting approaches that permit the isolation of relatively pure populations of carcinoma cells (Liu et al. 1997, 1999).

**Figure 1.** Histology of human prostate tissue. Panels A–D depict hematoxylin-eosin stains, while panels E and F show immunohistochemical analyses. [A] Low-power view showing the characteristic heterogeneity of prostate tissue, with this region containing a combination of BPH, PIN, and well-differentiated adenocarcinoma (CaP). (B) High-power view of a region in panel A, showing details of BPH and PIN. The region of BPH has ducts surrounded by basal cells [arrows], which are not found in the region of PIN. The area of PIN shows a transition within the same duct between normal and atypical hyperchromatic cells that contain larger nuclei with prominent nucleoli. (C) High-power view showing a nearby area of human prostate with a well-differentiated adenocarcinoma that is invading the peri-neural space [N marks the position of the nerve fiber]. Note that the carcinoma cells have large nuclei with very prominent nucleoli [arrows]. (D) View of a different prostate sample with high-grade PIN and a mixture of Gleason grade 4 and 5 carcinoma in the rest of the field. [E] Immunohistochemical staining of PIN and carcinoma using anti-cytokeratin 8, which marks all of the epithelial cells. These PIN lesions have a cribriform pattern [arrows], but are still within the confines of a prostatic duct. [F] Immunohistochemical staining of a tissue section containing both PIN and carcinoma using anti-cytokeratin 14, which marks the basal cells. Notably, the PIN displays inconsistent staining, whereas the carcinoma has no staining. All panels and interpretations were generously provided by Dr. Regina Gandour-Edwards and Dr. Robert Cardiff (School of Medicine, University of California–Davis, Davis, CA).
Limited number of established cell lines

Prostate cancer research has also been hampered by difficulties in generating permanent cell lines for in vitro studies. This limitation is undoubtedly related to the inherently slow growth of most prostate tumors and the low proliferation rate of the normal prostatic epithelium (e.g., Isaacs and Coffey 1989; Berges et al. 1995). Despite numerous attempts to obtain cell lines (discussed in Bright et al. 1997; Navone et al. 1999), only a handful of human prostate lines have been generated, of which the most commonly used (LNCaP, PC3, DU145, and TSU-Pr1) were isolated from metastatic lesions rather than primary tumors. This restriction implies that numerous conclusions in the literature are based on studies of a small repertoire of cell lines, even though the relevance of these cell lines for prostate carcinogenesis in vivo is uncertain.

Anatomy and development of the prostate

Comparison of the human and the murine prostate

The prostate gland surrounds the urethra at the base of the bladder and functions by contributing secretory proteins to the seminal fluid. Found exclusively in mammals, the prostate is not required for viability or even basal levels of fertility; therefore, its primary significance stems from its relevance for human disease. Indeed, it is intriguing to note that malignant prostatic tumors are among the most common neoplasia in men, whereas other ductal organs of the male urogenital system, such as the seminal vesicles and bulbourethral (Cowper’s) glands, are virtually immune to neoplasia.

In adult humans, the prostate is a small acorn-shaped tissue, with ductal–acinar histology, that lacks discernible lobular organization (Fig. 2A). In his classic work, McNeal defined three distinct morphological regions within the human prostate: the peripheral zone, the transition zone, and the central zone (McNeal 1969, 1988). The significance of this architecture is based upon the relationship of these zones to prostatic disease. Benign prostatic hyperplasia (BPH), a nonmalignant overgrowth that is fairly common among aging men, occurs mainly in the transition zone, and prostate carcinoma arises primarily in the peripheral zone.

In contrast with humans, the rodent prostate gland consists of four distinct lobes: anterior (also known as the coagulating gland), dorsal and lateral (collectively referred to as the dorsolateral lobe), and ventral (Fig. 2B). These lobes are arranged circumferentially around the bladder and display characteristic patterns of ductal branching and secretory protein production (Sugimura et al. 1986; Hayashi et al. 1991). There is no clear analogy between the lobular structure of the rodent prostate and the zonal architecture of the human prostate; indeed, although several studies assert that the dorsolateral lobe is most similar to the human peripheral zone, the evidence supporting this assertion is primarily descriptive. Notably, the dissimilar anatomy and morphology of the rodent prostate, together with the absence of spontaneous prostate cancer in laboratory rodents, has led to concerns about the relevance of rodent models for human prostate disease. Recent studies, however, strongly support the validity of rodent models for prostate cancer, as discussed below.

Formation and morphogenesis of the prostate

Formation of the prostate occurs during embryogenesis through epithelial budding from the urogenital sinus, a hindgut derivative that is of endodermal origin. During midgestation, the primitive urogenital sinus is separated from the terminal region of the hindgut through the division of the cloaca by the urorectal septum. The most rostral region (vesiculo-urethral part) of the primitive urogenital sinus forms the urinary bladder, whereas the

Figure 2. Schematic illustration of the anatomy of the human [A] and mouse [B] prostate (adapted from McNeal 1969 and Cunha et al. 1987, respectively).
most caudal region [phallic part] forms the penile urethra. The prostate gland originates from the intermediate region, known as the pelvic part [generally referred to as the urogenital sinus]. In the mouse, the prostatic buds first emerge at the rostral end of the urogenital sinus at approximately 17.5 days of gestation, toward the end of pregnancy. Subsequently, the prostatic epithelial buds undergo extensive ductal outgrowth and branching into the surrounding mesenchyme during the first three weeks of postnatal development [Sugimura et al. 1986; Timms et al. 1994]. Notably, although ductal morphogenesis is androgen dependent, the early postnatal period is marked by low levels of circulating androgens [Barkley and Goldman 1977; Jean-Faucher et al. 1978]. Although the overall process is similar in humans, the time course of prostate maturation differs significantly, since ductal morphogenesis largely occurs in response to high levels of androgen stimulation during puberty.

The analysis of the Nkx3.1 homeobox gene has recently provided insights into the earliest stages of prostate formation in the mouse [Sciavolino et al. 1997; Bhatia-Gaur et al. 1999]. Within the urogenital system, Nkx3.1 expression is first detected in the lateral aspects of the urogenital sinus epithelium prior to prostate formation, and subsequently marks all stages of prostate development. Notably, Nkx3.1 expression precedes formation of the prostatic buds by two days, and appears to correspond to the regions where prostatic buds will emerge, suggesting that regions of the urogenital sinus epithelium may have a differential capacity to form prostate [Bhatia-Gaur et al. 1999]. This idea is distinct from the previous view that the mesenchyme is solely responsible for inducing a passive epithelium.

The identification of additional regulatory genes and pathways expressed during prostate development represents an important avenue of future research. Current candidates for such regulatory genes include components of the Sonic hedgehog and BMP signaling pathways [Table 1; Dunn et al. 1997; Podlasek et al. 1999]. Given that carcinogenesis often involves deregulation of developmental regulatory genes, elucidation of the molecular pathways of prostate development should provide fresh insights into prostate cancer.

Epithelial–mesenchymal interactions in prostate development

As with many other tissues, prostate formation is initiated as a consequence of interactions between epithelial and mesenchymal tissues. The role of epithelial–mesenchymal interactions in prostate formation has been defined through elegant tissue recombination studies performed by Cunha and colleagues [Cunha et al. 1987; Cunha 1996; Hayward et al. 1997]. These tissue recombinations employ dissection and enzymatic isolation of epithelium and mesenchyme from embryonic urogenital sinus and/or from other tissues, which are then recombined in vitro and transplanted under the kidney capsule of adult male nude mouse hosts. The formation of prostatic tissue in these recombinants can subsequently be assessed by their histological appearance and by production of prostatic secretory proteins.

These tissue recombination studies have led to the following principal conclusions:

1. Prostatic differentiation requires both epithelial and mesenchymal components, in the absence of either, mature cell types fail to differentiate.
2. Specificity for the mesenchymal component is relatively stringent, because prostate will only form using mesenchyme from embryonic urogenital sinus [and under certain conditions, from seminal vesicle].
3. Specificity for the epithelial component is relatively broad, because a wide range of epithelia of endodermal origin, including those from differentiated male or female adult tissues, can form prostate when combined with urogenital sinus mesenchyme.
4. During prostate development, androgens initially act on the mesenchyme, because prostate does not form when urogenital sinus mesenchyme that is defective in androgen receptor [from a Testicular-feminization [Tfm] mutant] is combined with wild-type urogenital sinus epithelium. Subsequently, androgens act on the epithelium, for urogenital sinus epithelium defective in androgen receptor combined with wild-type mesenchyme forms prostatic ducts that lack production of prostatic secretory proteins. These results indicate that androgen signaling is required in the mesenchyme to produce signals for prostate induction and growth, and later in the epithelium for the secretory function of differentiated cell types.
5. Human epithelium and rodent mesenchyme [and vice versa] can be recombined to form prostate, supporting the validity of rodent prostate as a model for the human gland.

Because interactions between the epithelial and stromal components are essential for all stages of normal prostate growth and development, it is likely that aberrant interactions play a significant role in carcinoma. Although neoplastic foci arise in the epithelial compartment, the role of the stromal compartment in carcinogenesis has been relatively neglected. Notably, however, tissue recombination experiments have suggested that aberrant growth factor signaling from stromal components plays an integral role in cancer progression [Hayward et al. 1997; Olumi et al. 1999]. The signals that mediate such mesenchymal–epithelial interactions in carcinogenesis have not been identified, but may include members of the fibroblast growth factor [FGF] and transforming growth factor-β [TGFβ] families [Cunha 1996; Djakiew 2000].

Prostatic epithelial cell types and their relationship to carcinogenesis

Within the prostatic epithelium, there are at least three distinct cell types that can be distinguished by their morphological characteristics, functional significance, and relevance for carcinogenesis [Fig. 3]. The predominant cell type is the secretory luminal cell, a differentiated
### Table 1. Candidate regulatory genes for prostate development and carcinogenesis

<table>
<thead>
<tr>
<th>Gene</th>
<th>Product</th>
<th>Mouse and human phenotype</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Normal development</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Androgen receptor</td>
<td>Nuclear hormone receptor</td>
<td>Required in mesenchyme for initial formation of prostatic buds, and subsequently in epithelium for secretory protein production</td>
<td>(Cunha et al. 1987; Cunha et al., in press)</td>
</tr>
<tr>
<td>Nkx3.1</td>
<td>Homeodomain transcription factor</td>
<td>Expressed in prostatic regions of urogenital sinus epithelium and in newly formed prostatic buds; required for normal ductal morphogenesis and production of secretory proteins</td>
<td>(Bhatia-Gaur et al. 1999)</td>
</tr>
<tr>
<td>Shh</td>
<td>Secreted signaling factor</td>
<td>Expressed in urogenital sinus epithelium, anti-Shh antibodies inhibit prostate morphogenesis</td>
<td>(Podlasek et al. 1999)</td>
</tr>
<tr>
<td>BMP-4</td>
<td>Secreted member of TGFβ superfamily</td>
<td>Defective prostate morphogenesis in heterozygous mice</td>
<td>(Dunn et al. 1997)</td>
</tr>
<tr>
<td>FGF7</td>
<td>Growth factor</td>
<td>Stimulates prostatic growth in culture; mutant mice do not display prostatic defects</td>
<td>(Cunha et al., in press)</td>
</tr>
<tr>
<td>FGF10</td>
<td>Growth factor</td>
<td>Expression in prostate is androgen-regulated, stimulates growth of prostate epithelium</td>
<td>(Cunha et al., in press)</td>
</tr>
<tr>
<td>TGFβ1</td>
<td>Growth factor</td>
<td>Implicated as a regulator of androgen signaling, mutant mice display defects in prostatic duct formation</td>
<td>(Cunha et al., in press)</td>
</tr>
<tr>
<td>HoxD13</td>
<td>Homeodomain transcription factor</td>
<td>Expressed in the developing and adult prostate, mild defects in prostatic morphogenesis in mutant mice</td>
<td>(Podlasek et al. 1997)</td>
</tr>
<tr>
<td><strong>Initiation and progression to carcinoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NKX3.1</td>
<td>Homeodomain transcription factor</td>
<td>Prostatic epithelial hyperplasia and dysplasia followed by PIN in aged heterozygous and homozygous mutant mice; prostate-specific expression in human and mouse adult tissues; human gene maps to minimal deleted region of 8p21, but not mutated in human tumors</td>
<td>(He et al. 1997; Voeller et al. 1997; Bhatia-Gaur et al. 1999)</td>
</tr>
<tr>
<td>PTEN</td>
<td>Lipid phosphatase</td>
<td>Heterozygous mutant mice develop hyperplasia and dysplasia of multiple tissues including prostate; human gene maps to 10q23, but status of mutations is unresolved</td>
<td>(Li et al. 1997; Steck et al. 1997; Di Cristofano et al. 1998; Dong et al. 1998; Facher and Law 1998; Feilotter et al. 1998; Suzuki et al. 1998b; Vlietstra et al. 1998; Wang et al. 1998; Podsypanina et al. 1999)</td>
</tr>
<tr>
<td>MXI1</td>
<td>Transcription factor</td>
<td>Relatively mild prostatic epithelial hyperplasia and dysplasia in homozygous mutant mice; human gene maps to 10q24, but is infrequently mutated</td>
<td>(Eagle et al. 1995; Kawamata et al. 1996; Kuczynk et al. 1998; Prochownik et al. 1998; Schreiber-Agus et al. 1998)</td>
</tr>
<tr>
<td>Rb</td>
<td>Cell-cycle regulator</td>
<td>Homozygous mutant mice prone to hyperplasia, dysplasia and carcinoma in combined prostatic rescue and hormone induction model; human gene maps to 13q and functional studies suggest a critical role, but it is infrequently mutated</td>
<td>(Bookstein et al. 1990a; Bookstein et al. 1990b; Sarkar et al. 1992; Cooney et al. 1996b; Melamed et al. 1997; Li et al. 1998; Wang et al., in press)</td>
</tr>
<tr>
<td>p27</td>
<td>Cell-cycle regulator</td>
<td>Homozygous mutant mice develop hyperplasia and dysplasia of multiple tissues including prostate; loss of expression in human tumors correlates with tumor grade</td>
<td>(Fero et al. 1996; Kiyokawa et al. 1996; Nakayama et al. 1996; Guo et al. 1997; Cordon-Cardo et al. 1998; Cote et al. 1998; De Marzo et al. 1998a; Tsihlias et al. 1998; Yang et al. 1998)</td>
</tr>
<tr>
<td>p16</td>
<td>Cell-cycle regulator</td>
<td>Protein expression is up-regulated in carcinoma, but mutations are infrequent; limited information is currently available on the prostate phenotype of mutant mice or on the status of other INK family members</td>
<td>(Chen et al. 1996; Tamimi et al. 1996; Chi et al. 1997; Gaddipati et al. 1997; Mangold et al. 1997; Park et al. 1997; Gu et al. 1998)</td>
</tr>
</tbody>
</table>
androgen-dependent cell that produces prostatic secretory proteins. At the molecular level, luminal cells are characterized by their expression of androgen receptor, as well as cytokeratins 8 and 18 and the cell surface marker CD57 (Brawer et al. 1985; Nagle et al. 1987; Verhagen et al. 1988; Sherwood et al. 1990; Liu et al. 1997). The second major epithelial cell type corresponds to the basal cells, which are found between the luminal cells and the underlying basement membrane, and which form a continuous layer in the human prostate, but not

### Table 1. (Continued)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Product</th>
<th>Mouse and human phenotype</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telomerase</td>
<td>Ribonucleoprotein</td>
<td>Reduced telomere length and increased telomerase activity found in PIN and carcinoma</td>
<td>[Sommerfeld et al. 1996; Zhang et al. 1998]</td>
</tr>
<tr>
<td>Myc</td>
<td>Transcription factor</td>
<td>Amplified in some carcinomas; cooperates with RAS to induce hyperplasia in tissue recombinants</td>
<td>[Thompson et al. 1989; Van Den Berg et al. 1995; Bubendorf et al. 1999]</td>
</tr>
<tr>
<td>FGFs</td>
<td>Growth factors</td>
<td>Several family members, including FGF7 and FGF10, are implicated as regulators of prostatic growth; altered FGF function associated with progression in TRAMP mice</td>
<td>[Foster et al. 1998; Djaikiew 2000]</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>Cell adhesion</td>
<td>Reduced expression in PIN and carcinoma; loss may be associated with poor prognosis</td>
<td>[Umbas et al. 1992; Morton et al. 1993; Umbas et al. 1994]</td>
</tr>
<tr>
<td>c-CAM</td>
<td>Cell adhesion</td>
<td>Expression is reduced in PIN and lost in carcinoma</td>
<td>[Kleinerman et al. 1995]</td>
</tr>
<tr>
<td>Integrins</td>
<td>Cell interactions</td>
<td>Reduced expression of specific family members during cancer progression</td>
<td>[Cress et al. 1995]</td>
</tr>
<tr>
<td>c-Met</td>
<td>Tyrosine-kinase receptor</td>
<td>Overexpressed in PIN, carcinoma, and metastasis</td>
<td>[Pisters et al. 1995]</td>
</tr>
</tbody>
</table>

**Advanced carcinoma and metastasis**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Product</th>
<th>Mouse and human phenotype</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androgen receptor</td>
<td>Nuclear hormone receptor</td>
<td>Expression maintained even in androgen-independent tumors, although it is often amplified or mutated</td>
<td>[Bentel and Tilley 1996; Culig et al. 1998; Koivisto et al. 1998]</td>
</tr>
<tr>
<td>Bcl2</td>
<td>Apoptotic regulator</td>
<td>Overexpression confers resistance to apoptosis in androgen-independent disease; key target for clinical intervention</td>
<td>[Colombel et al. 1993; Apakama et al. 1996; Furuya et al. 1996; McDonnell et al. 1997; DiPaola and Aisner 1999]</td>
</tr>
<tr>
<td>IGF1</td>
<td>Growth factor</td>
<td>Promotes growth of prostate epithelium; elevated serum levels associated with cancer risk; overexpression of IGF1 in TRAMP mice associated with progression</td>
<td>[Chan et al. 1998; Kaplan et al. 1999; Djaikiew 2000]</td>
</tr>
<tr>
<td>TGFβ1</td>
<td>Growth factor</td>
<td>Negative regulator of prostate growth; shift to autocrine regulation associated with metastasis</td>
<td>[Djaikiew 2000]</td>
</tr>
<tr>
<td>EGF/TGFα</td>
<td>Growth factor</td>
<td>Stimulates prostatic epithelial cell growth and invasiveness; may provide a mechanism for overcoming androgen-dependence</td>
<td>[Djaikiew 2000]</td>
</tr>
<tr>
<td>Ka1</td>
<td>Putative integral membrane protein</td>
<td>Shown to suppress metastases; protein expression is down-regulated but is not mutated</td>
<td>[Dong et al. 1995; Dong et al. 1996]</td>
</tr>
</tbody>
</table>
In their now classic work, Isaacs and Coffey invoked the concept of a prostatic stem cell based on the regenerative capacity of the rat ventral prostate following castration-induced atrophy [Isaacs 1985; Kyprianou and Isaacs 1988; Isaacs and Coffey 1989]. In subsequent studies, analysis of cytokeratin expression patterns has identified transient populations of prostatic epithelial cells having both basal and luminal characteristics [Verhagen et al. 1992, Bonkhoff et al. 1994]. Based on these and other observations, as well as the properties of stem cells in other tissues, several groups have proposed the existence of a stem cell compartment within the prostatic epithelium [Bonkhoff and Remmerber 1996, De Marzo et al. 1998b]. This stem cell compartment is hypothesized to correspond to a subpopulation of androgen-independent basal cells. These stem cells would give rise to a transiently proliferating compartment, which are pluripotent androgen-responsive cells that in turn generate basal cells, differentiated luminal cells, and possibly the neuroendocrine cells. In support of this model, basal cells isolated by differential cell sorting can produce prostatic secretory proteins when cocultured with stromal cells [Liu et al. 1997]; however, there is no direct evidence that the resulting epithelial cells are bona fide luminal cells or that they originated from the input basal cells. Thus, a direct demonstration of the existence of stem cells within the basal cell layer as well as their multilineage potential is currently lacking.

Elucidation of the lineage relationships within the prostatic epithelium is relevant for understanding the origins of prostate carcinoma. Although prostate cancer cells often express basal cell markers, loss of the basal cell layer is paradoxically a hallmark of neoplastic foci [Fig. 1F; Totten et al. 1953; Bostwick and Brawer 1987; Bostwick 1996]. Moreover, since PSA is secreted exclusively by luminal cells, carcinoma cells have at least a partial luminal phenotype. One possible explanation for these observations is that transformed cells arise from the transiently proliferating progenitor compartment [De Marzo et al. 1998a,b], and thus may express characteristics of both the luminal and basal phenotype. Alternatively, neoplastic transformation might involve reversion of luminal cells to a less differentiated state that is reminiscent of the basal cell phenotype. Recently, prostate stem cell antigen (PSCA) has been identified as a cell surface marker that is expressed in normal basal cells and is up-regulated in prostate carcinoma [Reiter et al. 1998; Gu et al. 2000]. Although it is not specific for prostate, PSCA may represent a marker to help resolve the lineage relationships among prostatic epithelial cells and their relationship to carcinoma.

**Figure 3.** Schematic depiction of the cell types within a human prostatic duct. Note that the rare neuroendocrine cells are morphologically indistinguishable from basal cells.

In the mouse prostate. Basal cells express cytokeratins 5 and 14 as well as CD44 as well as low levels of androgen receptor [although this is controversial], but do not produce prostatic secretory proteins [Brawer et al. 1985; Nagle et al. 1987; Verhagen et al. 1988; Sherwood et al. 1990; Liu et al. 1997; Bui and Reiter 1998]. Consistent with a possible stem cell function [see below], basal cells also express factors that protect from DNA damage, such as the free-radical scavenger GSH and the anti-apoptotic gene Bcl2 [Bui and Reiter 1998; De Marzo et al. 1998b]. Finally, the third prostatic epithelial cell type is the neuroendocrine cell, a minor population of uncertain embryological origin, which is believed to provide paracrine signals that support the growth of luminal cells [di Sant’Agnese 1992, 1998; Abrahamsson 1999]. Neuroendocrine cells are androgen-independent cells dispersed throughout the basal layer that express chromogranin A, serotonin, and various neuropeptides.

Early studies had raised the possibility that neuroendocrine cells are derived from the migratory neural crest, a view that continues to garner some support [Aumuller et al. 1999]. However, the preponderance of current evidence favors an endodermal origin for neuroendocrine cells [like other prostatic epithelial cells], by analogy with a similar population of cells in the gut and pancreas [Andrew et al. 1983]. Whereas neuroendocrine cells represent a relatively minor population in the normal prostate, the accumulation of cells with neuroendocrine features, referred to as neuroendocrine differentiation, is a hallmark of more aggressive forms of prostate cancer [di Sant’Agnese 1992; Allen et al. 1995; Weinstein et al. 1996; McWilliam et al. 1997; Abrahamsson et al. 1998; Cussenot et al. 1998]. In most cases, cells with neuroendocrine features are dispersed within neoplastic foci, with increased neuroendocrine differentiation generally correlated with disease progression, but not necessarily with prognosis. In some cases, however, the neoplastic foci themselves are neuroendocrine, producing highly aggressive tumors that are termed small cell carcinoma.
will instead die of other causes. However, if not detected early, or in more aggressive forms of the disease, prostate carcinoma can advance to stages characterized by local invasion of the seminal vesicles, followed by metastasis primarily to the bone, usually resulting in lethality. This transition to metastatic disease is generally followed by a shift from androgen dependence to androgen independence, which is often provoked by androgen-ablation therapy.

Much research has focused on aspects of the clinical progression pathway that are pertinent issues for patient outcome. These aspects include: [1] identification of prognostic markers that distinguish the rare, aggressive forms of prostate cancer from the majority of indolent cancers; [2] understanding the mechanisms that lead to androgen independence; and [3] understanding how and why prostate cancer metastasizes preferentially to the bone. These issues have been extensively reviewed elsewhere (e.g., Harding and Theodorescu 1999; Lange and Vessella 1999; Pilat et al. 1999) and will not be discussed further here.

In contrast, less attention has been focused on the mechanisms underlying prostate cancer initiation, and on defining the parameters of a cancer progression pathway in molecular terms. One particularly fruitful area of investigation has been the analysis of chromosomal alterations that are commonly observed in prostate cancer. Therefore, as a starting point for discussion of a progression pathway, we will consider the characteristic patterns of chromosome abnormalities in prostate carcinoma as indicative of stages of prostate cancer progression (Fig. 4). Presumably, patterns of consistent allelic loss reflect the reduction or loss-of-function of putative tumor suppressor genes in prostate cancer. In particular, losses of heterozygosity at chromosomes 8p, 10q, 13q, and 17p are frequent events, and losses of 6q, 7q, 16q, and 18q have also been reported, although they are not as well characterized (Latil et al. 1994; Zenklusen et al. 1994; Takahashi et al. 1995; Cooney et al. 1996a; Cunningham et al. 1996; Elo et al. 1997; Latil et al. 1997; Saric et al. 1999). In addition, although chromosome gains appear to be less frequent than chromosome losses, gains at 8q and 7 are fairly common (Alcaraz et al. 1994; Bandyk et al. 1994; Van Den Berg et al. 1995).

Despite the significance of allelic loss for prostate carcinogenesis, no single candidate tumor suppressor gene has been definitively assigned a role in cancer progression. Several reasonable candidate genes (e.g., RB, p53, PTEN, NKX3.1) have been implicated, based on their localization to regions of allelic loss and their functional properties (Table 1, discussed below), but none of these has been shown to be mutated in a large percentage of prostate cancer specimens. Unfortunately, in most cases there are conflicting reports in the literature regarding the frequency and nature of mutations of specific candidate genes.

There are accordingly several general possibilities to consider in the case of each candidate tumor suppressor gene. The first and most obvious possibility is that the actual tumor suppressor genes in the regions of allelic loss have yet to be identified. A second possibility is that the ability to detect mutations in candidate genes may be masked by the inability to obtain relatively pure tissue samples for analysis, because of tumor heterogeneity and multifocality. This technical explanation is quite conceivable because most analyses are still performed with relatively large tissue samples that are unlikely to be homogeneous. However, new developments in PCR technology (e.g., real-time PCR) may help overcome these difficulties by allowing analysis of small numbers of cells. A third possibility is that candidate genes may be inactivated by a mechanism other than a coding region mutation, such as promoter methylation or mutations within regulatory sequences that may affect transcription, translation, or mRNA stability. In addition, inactivation could occur through alterations of upstream

Figure 4. Pathway for human prostate cancer progression. Stages of progression are correlated with loss of specific chromosome regions and candidate tumor suppressor genes.
or downstream components in a regulatory pathway; indeed, few studies have examined multiple components of a given pathway concurrently. A final possibility is that haploinsufficiency (loss of a single allele) may play an important role in prostate carcinogenesis, perhaps consistent with the slow rate of progression and indolent phenotype of most tumors.

**Mechanisms of prostate cancer initiation**

**PIN is a precursor of carcinoma**

Histopathological studies of prostate cancer tissue have led to the identification of a specific type of lesion that is believed to represent the primary precursor of human prostate cancer [Fig. 1D–F]. Known as PIN [McNeal and Bostwick 1986], this lesion can be classified into four common architectural types: tufting, micropapillary, cribriform, and flat [Bostwick and Brawer 1987; Nagle et al. 1991; Bostwick et al. 1993; Bostwick 1996, 1999]. PIN is recognized as a continuum between low-grade and high-grade forms, with high-grade PIN thought to represent the immediate precursor of early invasive carcinoma.

Several lines of evidence implicate high-grade PIN (HGPIN) as a preneoplastic lesion in humans. First, PIN lesions are primarily found in the peripheral zone, in proximity to invasive carcinoma [Bostwick and Brawer 1987]. Second, the appearance of HGPIN lesions generally precedes the appearance of carcinoma by at least 10 years, consistent with the idea of cancer progression [Sakr et al. 1993]. Third, allelic imbalance analysis has shown that PIN lesions are multifocal, as is the case for carcinoma; moreover, the chromosomal abnormalities found in PIN resemble those found in early invasive carcinoma, although they are less prevalent [Sakr et al. 1994; Qian et al. 1995; Vocke et al. 1996; Haggman et al. 1997b]. Fourth, the architectural and cytological features of PIN closely resemble those of invasive carcinoma, including disruption of the basal layer [Fig. 1F; Bostwick et al. 1993]. Finally, markers of differentiation that are commonly altered in early invasive carcinoma are also altered in PIN lesions [Nagle et al. 1991; Haggman et al. 1997a]. These include reduced expression of the cell adhesion protein E-cadherin and of the cytoskeletal component vimentin. On the other hand, PIN differs from invasive carcinoma in having an intact basement membrane, and thus does not invade the stroma [Fig. 1C,E; Bostwick et al. 1993]. A second distinction is that PIN lesions do not produce high levels of PSA; consequently, PIN can only be detected in biopsy samples, and not by serum testing [Haggman et al. 1997a]. Interestingly, PIN lesions are histologically similar to premalignant lesions of the breast—sometimes referred to as mammary intra-epithelial neoplasia [MIN]—[Tavassoli 1998; Cardiff et al. 2000], although there are also important distinctions (for discussion, see Bostwick et al. 1993).

Importantly, PIN lesions can be distinguished architecturally and cytologically from various other histopathological abnormalities of the prostatic epithelium, including benign prostatic hyperplasia (BPH) and atypical adenomatous hyperplasia (AAH), which are not believed to be precursor states for prostate cancer [Fig. 1B; Bostwick and Chang 1999]. In particular, BPH is primarily found in the transition zone, and its histological features typically include expansion of the basal layer and stromal hyperproliferation, neither of which is associated with carcinoma [McNeal 1978, 1988]. In contrast, the lesion described as proliferative inflammatory atrophy (PIA) has been proposed to be a precursor to PIN, and thus may represent an early step in carcinogenesis [De Marzo et al. 1999].

**Loss of chromosome 8p and NKX3.1**

One of the most common events in early prostate carcinogenesis is the loss of specific regions of chromosome 8p, which occurs in as many as 80% of prostate tumors, as well as in colorectal and lung carcinomas (Chang et al. 1994; Fujiwara et al. 1994; Matsuyama et al. 1994; Imbert et al. 1996, Wistuba et al. 1999). These chromosomal abnormalities have been detected by fluorescence in situ hybridization [FISH] [Macoska et al. 1993, 1994; Qian et al. 1995], comparative genomic hybridization [CGH] [Cher et al. 1994; Joos et al. 1995, Visakorpi et al. 1995b; Cher et al. 1996], and allelic imbalance analysis [Bergerheim et al. 1991; Bova et al. 1993; MacGrogan et al. 1994; Trapman et al. 1994; Emmert-Buck et al. 1995; Kagan et al. 1995; Suzuki et al. 1995; Cunningham et al. 1996; Vocke et al. 1996; Haggman et al. 1997b]. In prostate cancer, frequent losses occur at two, and possibly three [Macoska et al. 1995], regions of 8p, corresponding to 8p12-21 and 8p22. Many studies concur that loss of 8p12-21 is an early event in prostate carcinogenesis, occurring in both PIN lesions and early invasive carcinomas, whereas loss of 8p22 is a later event because it is common in more advanced carcinomas.

Several lines of evidence support the idea that the NKX3.1 homeobox gene is a candidate for the 8p1-21 locus. First, NKX3.1 maps within the critical region of 8p12-21 lost in human prostate cancers [Voeller et al. 1997]. Second, targeted gene disruption of Nkx3.1 in the mouse results in defects in prostate ductal morphogenesis and secretory function, consistent with a role for NKX3.1 in normal prostate differentiation [Bhatia-Gaur et al. 1999]. Finally, Nkx3.1 mutant mice develop PIN-like lesions that closely resemble human PIN [Bhatia-Gaur et al. 1999; M. Kim, M.M. Shen, and C. Abate-Shen, in prep.], suggesting that Nkx3.1 loss in mice models the predicted consequences of 8p12-21 loss in humans. On the other hand, mutations of the NKX3.1 coding sequence have not been detected in prostate carcinomas using SSCP analysis [Voeller et al. 1997], nor is NKX3.1 mRNA lost in prostate tumors [Xu et al. 2000]. However, loss of a single Nkx3.1 allele in mice is sufficient for development of PIN lesions, raising the possibility that haploinsufficiency at 8p12-21 could account for the lack of NKX3.1 mutations in human cancer. In summary, although the evidence is far from unequivocal...
cal, NKX3.1 is likely to represent a regulatory gene whose loss is involved in prostate cancer initiation.

Since expression of NKX3.1 is restricted to the prostate in adult tissues [He et al. 1997; Bhatia-Gaur et al. 1999], its loss or inactivation is unlikely to be relevant for lung or colorectal carcinomas, which also have deletions of 8p [Chang et al. 1994; Wistuba et al. 1999]. Thus, 8p22 may harbor one or more tumor suppressor genes with broad-spectrum activities, in contrast to NKX3.1, which appears to be prostate-specific. A detailed map of 8p22 has been obtained [Bova et al. 1996], but candidate tumor suppressor genes in this region have not yet been identified.

**Mechanisms of prostate cancer progression**

**Loss of chromosome 10q and PTEN**

Several parallels can be drawn between losses of chromosomal regions 10q and 8p in prostate cancer. First, loss of 10q is a frequent event (~50%–80%) that has been detected by several independent strategies, including FISH, CGH, allelic imbalance, and cytogenetics [Carter et al. 1990b, Bergerheim et al. 1991, Macoska et al. 1993, Sakr et al. 1994, Gray et al. 1995, Cher et al. 1996, Ittmann 1996, Trybus et al. 1996, Saric et al. 1999], and also occurs frequently in other carcinomas [e.g., Kim et al. 1998]. Second, at least two independent loci are involved that map to 10q23.1 and 10q24–q25. Finally, while several attractive candidates are found at these loci, their involvement in prostate carcinogenesis has not been established unequivocally. Importantly, loss of 10q is thought to be a later event in cancer progression than loss of 8p, because it occurs more frequently in carcinoma and less frequently in PIN lesions.

Among potential candidate genes, PTEN/MMAC1 maps to 10q23, in a region that is lost in prostate carcinomas as well as several other carcinomas, including glioblastoma, breast, and endometrial cancers [for review, see Di Cristofano and Pandolﬁ 2000]. PTEN mutations are frequently detected in patients with three autosomal dominant disorders—Cowden’s disease, Hermite-Duclos disease, and Bannayan-Zonana syndrome [Liaw et al. 1997]—whose syndromes share similar pathological features including the formation of benign tumors and an increased susceptibility to malignant cancer. PTEN encodes a lipid phosphatase whose main substrate is PIP-3; loss of PTEN function therefore results in activation of PKB/AKT kinase activity, which in turn leads to decreased sensitivity to cell death. However, PTEN loss has also been associated with aberrant cellular proliferation [Sun et al. 1999], which suggests that its actual function may be dependent upon cellular context. Pten is widely expressed during mouse embryonic development and adulthood [Luukko et al. 1999], and targeted gene disruption results in homozygous embryonic lethality [Di Cristofano et al. 1998; Suzuki et al. 1998a, Podsypanina et al. 1999]. Notably, Pten heterozygous mice develop severe dysplasia and carcinoma of several distinct cell types, including colon and skin.

Several lines of evidence implicate loss of PTEN as a key event in human prostate carcinogenesis. In the original characterization of the gene, PTEN was found to be mutated in all four prostate cell lines examined [Li et al. 1997; Steck et al. 1997]. It was subsequently shown that PTEN is frequently lost in prostate cell lines and xenografts [Vlietstra et al. 1998], that it undergoes homozygous deletions in ~10% of primary prostate tumors [Wang et al. 1998], and that alterations are more frequent in metastatic prostate cancer [Suzuki et al. 1998b]. On the other hand, several studies have reported that mutations of PTEN are relatively rare in prostate carcinoma [Dong et al. 1998, Facher and Law 1998, Feilotter et al. 1998, Pesche et al. 1998]. However, a functional role for PTEN in prostate carcinogenesis has been supported by immunohistochemical data showing reduced expression of PTEN protein in primary tumors and xenografts [Whang et al. 1998; McMenamin et al. 1999], as well as increased AKT activity in xenograft models [Wu et al. 1998]. Moreover, Pten heterozygous mutant mice develop prostatic epithelial hyperplasia and dysplasia [Di Cristofano et al. 1998; Podsypanina et al. 1999], consistent with the growth suppressive activities of PTEN in prostate carcinoma cell lines [Davies et al. 1999, Sun et al. 1999]. Therefore, despite the lack of reported mutations of PTEN in primary tumors, the evidence in favor of a central role for PTEN in prostate carcinogenesis is compelling.

Besides PTEN, a second candidate gene mapping to 10q25 is MXII, which encodes a Myc-binding protein [Eagle et al. 1995]. MXII protein is of particular interest given its intimate association with Myc protein, which has also been suggested to play a role in prostate cancer since it maps to a frequently amplified region of chromosome 8q [Van Den Berg et al. 1995; Bubendorf et al. 1999]. However, although Mxi1 mutant mice have been reported to display prostatic epithelial hyperplasia and dysplasia [Schreiber-Agus et al. 1998], this phenotype is relatively mild. In addition, despite initial reports suggesting that MXII1 is mutated with high frequency [Eagle et al. 1995, Prochownik et al. 1998], subsequent studies have failed to detect mutations in primary tumors [Kawamata et al. 1996, Kuczyk et al. 1998].

**Loss of chromosome 13q and Rb**

Loss of chromosome 13q, including a region containing the Retinoblastoma [Rb] gene, occurs in at least 50% of prostate tumors [Cooney et al. 1996b; Melamed et al. 1997; Li et al. 1998]. Indeed, early studies showed that reintroduction of Rb into prostate carcinoma cell lines lacking Rb inhibited tumorigenicity [Bookstein et al. 1990b]. In subsequent work, mutations of the Rb gene and loss of Rb protein expression have been reported in clinically localized as well as more advanced prostate carcinomas [Bookstein et al. 1990a, Phillips et al. 1994, Ittmann and Wieczorek 1996]. Notably, Rb has been implicated in regulating apoptosis of prostate cells, particularly in response to androgens [Zhao et al. 1997; Bowen et al. 1998, Yeh et al. 1998]. Furthermore, embryonic
prostatic rescue and tissue recombination approaches have shown that homozygous loss of Rb results in dysplasia and invasive carcinoma, which can be exacerbated by hormonal stimulation (Wang et al. 2000). Several other studies, however, have failed to demonstrate mutations of Rb (Sarkar et al. 1992; Cooney et al. 1996b; Li et al. 1998), leading to the suggestion that loss of an alternative gene at 13q may be more significant for prostate carcinogenesis [e.g., Wieland et al. 1999]. In a recurring theme, therefore, several lines of evidence have implicated Rb in prostate carcinogenesis, but definitive evidence is currently lacking.

**Altered cell-cycle regulatory genes**

In normal prostate epithelium, the relatively low rate of cell proliferation is balanced by a low rate of apoptosis [Berges et al. 1995]. In contrast, PIN and early invasive carcinomas are characterized by a seven- to 10-fold increase in the proliferation rate, whereas advanced and/or metastatic prostate cancers also display an approximately 60% decrease in the rate of apoptosis. Altered cell-cycle control is therefore likely to play a role in progression of clinically localized disease, whereas deregulated apoptosis may be more important for advanced carcinoma.

Among cell cycle regulatory genes, loss of function of the CDK4 inhibitor p27kip1 is particularly prevalent in prostate tumors, and may provide a prognostic marker of patient outcome [for review, see Maer and Lodish 1999; Tsihlias et al. 1999]. Notably, p27kip1 maps to 12p12-13.1 [Pietenpol et al. 1995; Ponce-Castaneda et al. 1995], a region of frequent deletion in advanced prostate cancer [Kibel et al. 1998]. Although loss of p27kip1 activity occurs frequently in many carcinomas, including breast and colon cancers, p27kip1 is rarely mutated. Instead, p27kip1 inactivation occurs through loss of expression or altered subcellular localization as a consequence of aberrant phosphorylation and/or ubiquitylation [Esposito et al. 1997; Loda et al. 1997; Tan et al. 1997; Singh et al. 1998]. In the prostate, several studies have demonstrated that loss of p27 protein expression correlates with tumor grade [Guo et al. 1997; Cote et al. 1998; De Marzo et al. 1998a; Tsihlias et al. 1998; Yang et al. 1998b], and does not occur in BPH [Cordon-Cardo et al. 1998]. Moreover, a functional role for p27kip1 in prostate carcinogenesis has been suggested by targeted gene disruption, which results in hyperplasia of multiple tissues including the prostate [Fero et al. 1996; Kiyokawa et al. 1996; Nakayama et al. 1996], and by the synergism between loss of p27kip1 with loss of Rb in tumorigenesis [Park et al. 1999]. Haploinsufficiency of p27kip1 has also been shown to play a key role in tumor formation in several tissues in a mouse model [Fero et al. 1998], although the prostate was not examined in this study.

Another cell cycle regulator of particular interest is p16, because its alteration is inversely correlated with that of Rb in other carcinomas [Otterson et al. 1994; Lukas et al. 1995; Ueki et al. 1996], and its loss is significant for bypassing senescence in many cell types, including prostate epithelial cells [Jarrard et al. 1999]. However, with few exceptions [Chi et al. 1997], most studies have reported that p16 is rarely mutated in primary prostate carcinomas, but is instead mutated in advanced metastatic disease [Chen et al. 1996; Tamimi et al. 1996; Gaddipati et al. 1997; Mangold et al. 1997; Park et al. 1997; Gu et al. 1998], although none of these studies examined the status of Rb in parallel. It has been suggested that in primary tumors, inactivation of p16 may occur by deletion of one allele, combined with promoter methylation of the remaining allele [Jarrard et al. 1997]. Surprisingly, up-regulation (rather than loss) of p16 protein has been reported to be a prognostic marker of disease recurrence in prostate cancer [Lee et al. 1999; Halvorsen et al. 2000]. Although it is difficult to provide a mechanistic explanation for this finding, similar observations have been observed in other carcinomas [e.g., Dong et al. 1997].

In contrast to p27 and p16, the potential roles of other cell cycle regulatory genes in prostate cancer have not been thoroughly examined. For instance, overexpression of cyclin D1 is rare in primary prostate tumors [Gumbiner et al. 1999], but is found in metastases as well as in prostate cell lines [Han et al. 1998; Drobnjak et al. 2000]. In addition, although mutations of p21 have not been reported in other human cancers, a somatic mutation of p21 was identified in human prostate cancer [Gao et al. 1995], and it has been proposed that p21 protein expression may predict tumor recurrence [Aaltomaa et al. 1999; Sarkar et al. 1999].

**Aging and telomerase**

Aging appears to be the most critical factor in progression from HGPIN to early invasive carcinoma, but is the least well understood. This strong correlation of aging and onset of prostate carcinoma may be caused by the low proliferation rate of the prostatic epithelium, and the subsequently longer duration required for transforming events to occur. It is likely that this role of aging is also related to the activity of telomerase in overcoming replicative senescence in prostate carcinoma cells. Notably, PIN lesions and prostatic carcinoma, but not BPH, display reduced telomere length with a concomitant increase in telomerase activity [Sommerfeld et al. 1996; Zhang et al. 1998]. The recent development of mouse models with telomerase dysfunction should facilitate such functional studies of telomerase activity in prostate carcinogenesis [Lee et al. 1998].

**Mechanisms of progression to advanced carcinoma and metastatic disease**

**Androgen receptor signaling and cancer progression**

The most common treatment for advanced prostate cancer is androgen-ablation therapy, which effectively results in tumor regression over the short-term caused by massive apoptosis of androgen-dependent carcinoma...
cells [Huggins and Hodges 1941]. In most cases, however, such treatment ultimately results in the recurrence of highly aggressive and metastatic prostate cancer that is androgen independent. This transition to androgen independence is likely to occur through selection for growth of androgen-independent cells that may already coexist within an androgen-dependent population prior to androgen deprivation [Isaacs and Coffey 1981; Gingrich et al. 1997]. Because of these clinical implications, much research has focused on understanding how prostate cancer cells are able to escape their initial androgen dependence, as well as on the status of the androgen receptor (AR) when this occurs [for review, see Bentel and Tilley 1996; Culig et al. 1998; Koivisto et al. 1998].

Initially, it was believed that androgen-independent tumor growth was caused by loss of expression of AR mRNA and protein, because AR is not expressed in highly aggressive and/or metastatic rodent and human cell lines [Tilley et al. 1990, Culig et al. 1998]. Contrary to expectations, however, it was subsequently shown that AR protein is expressed fairly homogeneously in primary tumors, recurrent local tumors, and even in metastases [van der Kwast et al. 1991; Ruizeveld de Winter et al. 1994; Hobisch et al. 1995; Sweat et al. 1999]. These observations imply that carcinoma cells bypass the requirement for androgens through a mechanism that does not involve down-regulation of AR expression.

There appear to be several possible mechanisms for acquiring androgen independence, including alterations of AR activity, function, and/or specificity. One possibility is that AR function becomes highly sensitized to low levels of residual androgens. Indeed, AR is frequently mutated within the hormone-binding domain in both cell lines and primary tumors, rendering AR permissiveness for binding other steroid hormones, and thereby overcoming a specific requirement for androgens [Trapman et al. 1990, Veldscholte et al. 1992; Gaddipati et al. 1994; Elo et al. 1995].

However, AR mutations are found not only in the hormone-binding domain, but also throughout its coding region in primary tumors as well as in hormone-refractory disease [Newmark et al. 1992; Taplin et al. 1995; Tilley et al. 1996; for review, see Bentel and Tilley 1996]. Other mutations that affect AR activity include amplification of CAG repeats, the length of which is inversely correlated with androgen action [Hakimi et al. 1996], and amplification of the entire AR gene, which may be prevalent in recurrent disease [Visakorpi et al. 1995a, Koivisto et al. 1998]. Finally, it has been suggested that in cases when androgens are limiting [as occurs following androgen-ablation therapy], hormone requirements may be bypassed through synergistic activities of AR with growth factors such as IGF, FGF, and/or EGF [e.g., Culig et al. 1994].

**Loss of 17p and p53**

Loss of chromosome 17p occurs in advanced stages of prostate cancer and metastatic disease [Cher et al. 1994, 1996; Saric et al. 1999], deleting a region that includes the p53 locus, but not BRCA1 [Brooks et al. 1996]. It is now generally accepted that mutations of p53 occur infrequently in early invasive carcinoma [Henke et al. 1994; Voeller et al. 1994; Prendergast et al. 1996], although not all studies concur [Chi et al. 1994]. In contrast, p53 is mutated in advanced stages of prostate cancer, as well as in recurrent and metastatic disease, as inferred by immunocytochemical localization of accumulated protein [presumed to be indicative of its mutation] or by direct mutational analysis [Bookstein et al. 1993; Effert et al. 1993; Navone et al. 1993; Aprikian et al. 1994; Eastham et al. 1995; Heidenberg et al. 1995], again with dissenting reports [Dinjens et al. 1994]. Moreover, several studies indicate that p53 overexpression is a predictive factor for poor prognosis and disease recurrence, particularly when detected in combination with Bcl2 [Thomas et al. 1993; Shurbaji et al. 1995; Bauer et al. 1996; Moul et al. 1996; Matsushima et al. 1997; Theodorescu et al. 1997; Brewster et al. 1999; Stackhouse et al. 1999].

Interestingly, the frequency of p53 mutations seems to be lower in prostate cancer than in other cancers. A relatively minor role for p53 in prostate carcinogenesis is consistent with the observation that Li-Fraumeni patients carrying germline p53 mutations have a low incidence of prostate cancer [Kleihues et al. 1997], although it may be the case that they succumb to other carcinomas before they can develop prostate cancer. An alternative possibility is that the variability in reported p53 mutation rates reflects a differential tissue-specific role of other components in the p53 pathway, particularly mdm2 and p21 [Osman et al. 1999]. A final possibility is that p53 mutations occur frequently in prostate cancer, but are difficult to detect, since they appear to be associated with more highly aggressive and/or recurrent forms of the disease, for which tissue acquisition is more difficult [Visakorpi et al. 1992; Yang et al. 1996].

**Altered apoptotic regulatory genes**

Overexpression of Bcl2 in prostate carcinoma cells is a hallmark of advanced, hormone-refractory disease, and may account for the resistance to apoptosis that is characteristic of late stages [Colombel et al. 1993; Apakama et al. 1996; Furuya et al. 1996; McDonnell et al. 1997]. Although Bcl2 expression is restricted to basal cells in the normal prostate [Hockenbery et al. 1991], forced expression of Bcl2 in LnCAP prostate carcinoma cells protects against apoptosis induced by androgen depletion [Raffo et al. 1995]. Moreover, as is the case for p53, Bcl2 expression may provide a prognostic marker that correlates with disease outcome [Bubendorf et al. 1996; Keshgegian et al. 1998; Mackey et al. 1998]. Indeed, several preliminary studies have examined whether Bcl2 inactivation may prevent tumor recurrence [Dorai et al. 1997; Gleave et al. 1999; Miyake et al. 1999]. Overexpression of Bcl2 has been shown to confer resistance to chemotherapy in prostate carcinoma cell lines [Tu et al. 1995], and current clinical efforts are aimed at modulating the expression of Bcl2 [DiPaola 1999]. Nonetheless, the sig-
nificance of Bcl2 activity in prostate cancer remains unclear, and other components of the apoptotic pathway have not been extensively examined [Krajewska et al. 1996; Johnson et al. 1998]. Notably, transgenic mice in which Bcl2 was overexpressed in the prostate had a relatively mild phenotype [Zhang et al. 1997], which perhaps reflects relatively low-level transgene expression, rather than lack of Bcl2 activity.

Murine models for prostate cancer

Historically, a major limitation in studying prostate cancer has been the lack of suitable animal models that faithfully recapitulate all stages of disease progression [for review, see Navone et al. 1999]. As a notable exception, dogs have been widely studied because they develop spontaneous high-grade PIN and prostate carcinoma as a correlate of aging, and display progression to androgen independence and metastasis to bone [Waters et al. 1998]. Moreover, most animal models of prostate cancer are not amenable to genetic analyses.

The validity of the mouse as a model for prostate cancer has met with considerable controversy because of the absence of spontaneous prostate cancer in mice and the cross-species differences in prostate anatomy and morphology. Despite these concerns, many laboratories have undertaken the generation and use of xenograft and hormone-induction models, and more recently transgenic and knockout approaches. In particular, the prostate phenotypes of several transgenic and knockout mouse models appear closely analogous to the human disease, although these fail to display preferential metastasis to bone.

Xenograft, reconstitution, and hormonal carcinogenesis models

Despite difficulties in propagating human prostate tumors in immunodeficient mouse hosts, several groups have successfully generated xenografts that provide models for clinically advanced prostate cancer, as well as sources of human prostate cancer cell lines (e.g., Ellis et al. 1996; Klein et al. 1997). These xenograft models have been particularly valuable for studying the mechanisms involved in the transition to androgen independence [Craft et al. 1999] and correspond to one of the few available approaches for studying bone metastasis in mice. In addition, the discovery by Dunning of the rare, spontaneous occurrence of prostate cancer in an inbred Copenhagen rat has provided the basis for a set of serially transplantable murine cell lines that represent the spectrum from androgen-dependent, nonmetastatic carcinoma to androgen-independent, highly metastatic disease [Isaacs et al. 1986]. These Dunning lines have been widely used in tumorigenicity studies employing subcutaneous or orthotopic inoculations, particularly for gene transfer approaches to identify chromosomal regions that contribute to metastases [Ichikawa et al. 1994; Rinker-Schaeffer et al. 1994]. Finally, in vivo model systems to study stromal–epithelial interactions have used mixing of LNCaP cells with bone stromal cells, followed by injection into immunodeficient mouse hosts [Thalmann et al. 1994; Wu et al. 1994].

A conceptually related xenograft methodology has been developed in the mouse reconstituted prostate (MRP) model, which represents a variation of the tissue recombination technique discussed above. In this approach, urogenital sinus epithelium or mesenchyme is infected with retroviruses encoding dominantly acting oncogenes such as Myc or Ras, followed by recombination with the counterpart mesenchyme or epithelium and grafting under the renal capsule [Thalmann et al. 1989; Lu et al. 1992]. This approach was initially used to demonstrate synergy of Myc- and Ras-induced transformation, and subsequently to demonstrate a role for p53 loss in clonal expansion during cancer progression, as traced by analysis of unique retroviral integration sites [Thompson et al. 1989; Lu et al. 1992]. Until recently, however, a primary limitation for this approach has been the low infectivity (∼1%) of primary prostatic epithelial cells [Thompson et al. 1989]. This restriction can now be overcome using immortalized cell lines that are capable of reconstituting prostatic tissue in tissue recombination experiments, as well as improved retroviral vectors that allow for higher titer infectivity.

Finally, hormone-inducible models were originally developed to test the hypothesis that altered androgen to estrogen ratios contribute to the onset and progression of prostate cancer [Mawhinney and Neuhauer 1979]. Indeed, subcutaneous implantation of capsules containing large doses of testosterone and estrogen results in highly reproducible progression from prostatic epithelial hyperplasia to invasive carcinoma. Although this methodology was initially developed in Noble rats [Leav et al. 1989; Wang and Wong 1998], recent adaptations have allowed the investigation of hormonal carcinogenesis in mutant mouse models [Wang et al. 2000].

Transgenic models

The identification of promoter elements that direct specific transgene expression to the prostate has facilitated the development of several mouse models of prostate cancer. In particular, the widely used promoter elements from the rat probasin gene can direct transgene expression to the ventral and dorsolateral prostate and to a lesser extent to the anterior prostate [Greenberg et al. 1994; Yan et al. 1997]. Notably, a line of transgenic mice, known as the TRAMP [transgenic adenocarcinoma mouse prostate] model, contains a minimal probasin promoter driving expression of SV40 large T and small t tumor antigens. These transgenic mice display high-grade PIN and/or prostate cancer within 12 weeks of age [Fig. 5], and ultimately develop metastases by 30 weeks primarily to the lungs and lymph nodes, and less often to bone, kidneys, and adrenal gland [Greenberg et al. 1995; Gingrich et al. 1996, 1997]. Androgen depletion by castration results in variably decreased tumor incidence, but ultimately results in appearance of androgen-inde-
However, the utility of these lines is limited by the onset of tumors in multiple tissue sites; moreover, the primary occurrence of androgen-independent tumors in the ventral prostatic lobe may limit their relevance for human cancer. Aside from the probasin and C3(1) promoters, few other prostate-specific promoters have been defined; notably, the human PSA promoter appears to be of limited usefulness in transgenic models [Schaффner et al. 1995].

A different category of transgenic models comprises those that develop neuroendocrine tumors of a highly aggressive nature [Skalnik et al. 1991; Perez-Stable et al. 1997; Garabedian et al. 1998, Lakshmanan et al. 1999], similar to human tumors with neuroendocrine differentiation. These models include Cryptdin-2 promoter–SV40 T antigen mice, which rapidly develop PIN lesions followed by aggressive androgen-independent carcinomas that readily metastasize [Garabedian et al. 1998]. Another transgenic model has used the fetal Gγ-globin promoter linked to SV40 T antigen, which directs transgene expression to the prostate in a single line, presumably owing to chromosome integration context, leading to metastatic androgen-independent tumors with neuroendocrine differentiation [Perez-Stable et al. 1997]. Finally, a gp91–phox transgene construct can fortuitously direct expression of SV40 early region to the prostate in several independent lines, again resulting in rapid onset of poorly differentiated neuroendocrine carcinomas [Skalnik et al. 1991]. In each of these cases, there is no indication of an androgen-dependent stage prior to carcinoma formation; in addition, widespread transgene expression in other tissues limits their overall utility.

**Knockout models**

Relatively few mutant mouse models have been reported to display prostatic epithelial hyperplasia and dysplasia; among these are the Nkx3.1 and Pten mutant mice discussed above. Somewhat surprisingly, targeted disruption of numerous other tumor suppressor genes has not been reported to produce such prostatic epithelial defects. One likely explanation is that such mice may die of unrelated developmental defects or may succumb to
tumors in other tissues before developing prostate cancer; an alternative possibility is that the prostate phenotype has not been examined.

Consequently, the creation of mouse reagents for prostate-specific gene targeting is a high priority, since it is likely to facilitate the development of additional mouse models for prostate cancer. Notably, probasin-Cre recombinase transgenic mice that may be suitable for Cre-loxP-mediated gene deletion in the prostate have recently been described [Maddison et al. 2000]. Also of note, tissue rescue approaches that use renal capsule grafts of isolated urogenital anlage should allow investigation of the prostate phenotype of mutants that display mid-late gestation embryonic lethality [Wang et al. 2000]. In combination, these approaches should circumvent many of the traditional barriers for reverse genetic analysis of prostate development and cancer.

Future directions

A primary goal for future research will be to establish a definitive molecular pathway of prostate cancer initiation and progression, accompanied by a precise understanding of the functional roles of candidate genes and regulatory pathways. Achieving this objective will require overcoming the significant obstacles imposed by limited availability of homogeneous genetic material from human prostate cancer specimens. The continued development of sensitive techniques for isolation and analysis of limited quantities of genomic DNA and mRNA should help overcome these limitations. In addition, the molecular identification and analysis of familial susceptibility genes for prostate cancer may provide critical breakthroughs in this endeavor.

Further advances in prostate cancer research will require a paradigmatic shift away from descriptive studies toward mechanistic and/or molecular analyses. Until recently, mouse models have been underutilized, perhaps owing to seemingly unwarranted concerns about the validity of the mouse as a model for human prostate cancer. Nonetheless, it is already evident that transgenic and mutant mice have provided excellent genetic models to dissect pathways of prostate carcinogenesis, and will obviously assume an increasingly significant role in the future. Along the way, this will require the characterization of additional prostate-specific promoters for the development of transgenic mice, as well as the development of mouse reagents for tissue-specific knockouts. In addition, the integration of prostate reconstitution strategies with improved retroviral gene transfer methodologies should provide an excellent approach for defining molecular components of a progression pathway.

In summary, although the molecular biology of prostate cancer has only just emerged from its infancy, the adolescent maturation of this field appears likely in the not-too-distant future. In particular, the advent of sophisticated mouse models will undoubtedly lead to crucial developments in our understanding of this much-feared disease.

Acknowledgments

We are indebted to Robert Cardiff for providing images of human histopathology, and to Jeffrey Gingerich and Norman Greenberg for providing images of TRAMP mouse histology. We also thank Robert Cardiff, Ron DePinho, Robert DiPaola, Norman Greenberg, Simon Hayward, and Arnold Rabson for critical reading of the manuscript. We apologize to those researchers whose work we have not been able to cite because of space constraints. Research in the laboratories of C.A.-S. and M.M.S. is supported by grants from the NIH (ROI CA76501, U01 CA 84294), the Department of Defense (DAMD17-98-1-8532, PC991476), and the Gustavus and Louise Pfeiffer Research Foundation.

References


Molecular genetics of prostate cancer


Cher, M.L., Bova, G.S., Moore, D.H., Small, E.J., Carroll, P.R.,
Abate-Shen and Shen


Molecular genetics of prostate cancer


implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11: 2121–2126.


Molecular genetics of prostate cancer

906.


